Partner with the Centre for Drug Development

We collaborate with leading industry and academic partners worldwide to advance the clinical development of promising cancer therapeutics.

As a partner, you can access our expertise in the early phase clinical development of small molecules, antibodies, vaccines, drug conjugates and other therapeutic modalities.

We're thrilled to advance KJ-103 into the clinic in partnership with Cancer Research UK. KJ-103 is the first of a new wave of antibodies to come from our modernised technology platform that leverages AI grounded in biology to create transformative antibody therapeutics.

- David Young, co-founder and CEO of KisoJi 

Clinical development partnerships

Supported by an expert network of investigators, we leverage our drug development capabilities, expertise and infrastructure to demonstrate clinical potential.

We are motivated by delivering patient benefit, focusing on innovative, first-in-class agents and science-driven first-in-human trials.

How do our clinical development partnerships work?

We work with our partners to design, set-up and deliver clinical trials via our UK-wide and European network of investigators and early phase clinical trial centres. We take responsibility for all trial sponsor activities, helping complete preclinical packages, delivering regulatory submissions, clinical study management and ongoing medical support.

Our partners retain their background IP and receive a licence to the clinical trial results and all collaboration IP.

Our flexible co-development partnership model operates on a shared risk-reward basis offering a cost effective way for partners to progress the development of cancer therapies. We aim to recover a portion of our costs during the partnership and receive a fair share of future revenues if the agent is successful.

Discover our current portfolio

Email us to discuss partnering opportunities  

Partnering with Cancer Research UK gives us a unique opportunity to make a real difference. We look forward to developing this partnership further with our shared competence, funding, and core vision of improving the lives of those affected by cancer.

- Ingrid Stenstadvold Ross, General Secretary of the Norwegian Cancer Society

Agents originating from academic research

We offer sponsorship of promising agents arising from academic research through our Drug Development Project scheme. Although our clinical trials are conducted in the UK and Europe, our partners are based around the world.

If you are based outside of the UK and have a cutting-edge oncology therapeutic, contact us to find out more about how we can help you develop it.  All potential projects from both industry partners and academics are confidentially evaluated by our New Agents Committee through the Drug Development Project scheme.

Learn more about the scheme

Find out about our New Agents Committee    

A snapshot of our partners

Academic and non-profit

Pharmaceutical and biotech

You might also be interested in

Two women standing in a room facing each other smiling.

Hear more from the Centre for Drug Development

Discover the latest news and press releases related to our work, including partnering, clinical trials and patient involvement activities.

The Centre for Drug Development leadership team.

Meet the team

At the Centre for Drug Development, we have a team of over 100 scientists and operational staff located across the UK. Our in-house expertise includes translational science, preclinical transition, biomarker strategy and bioanalysis, medical oncology, trial design, protocol generation and pharmacovigilance.

Two people embracing while a third sits nearby at a table. It appears to be a family gathering for lunch.

Involving patients in our work

From clinical trial planning to patient-centred trial management apps, we’re consulting, collaborating and partnering with people affected by cancer.